Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform Read more about Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform
BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD Read more about BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD
BioSenic réalise une nouvelle analyse approfondie de ses données cliniques positives de phase 2 en vue d'un schéma d'administration optimal pour son prochain essai clinique de phase avancée sur le trioxyde d'arsenic (ATO) ciblant la cGvHD Read more about BioSenic réalise une nouvelle analyse approfondie de ses données cliniques positives de phase 2 en vue d'un schéma d'administration optimal pour son prochain essai clinique de phase avancée sur le trioxyde d'arsenic (ATO) ciblant la cGvHD
Transparency notification received from Véronique Pomi Read more about Transparency notification received from Véronique Pomi
Notification de transparence reçue de la part de Véronique Pomi Read more about Notification de transparence reçue de la part de Véronique Pomi
Medsenic, subsidiary of BioSenic SA, extends key patent to the United States Read more about Medsenic, subsidiary of BioSenic SA, extends key patent to the United States
Medsenic, filiale de BioSenic SA, étend un brevet clé aux États-Unis Read more about Medsenic, filiale de BioSenic SA, étend un brevet clé aux États-Unis
Nouveaux accords de licence et de commercialisation avec Phebra PTY Ltd Read more about Nouveaux accords de licence et de commercialisation avec Phebra PTY Ltd
New set of licensing and commercialization agreements with Phebra PTY Ltd Read more about New set of licensing and commercialization agreements with Phebra PTY Ltd
